Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$519.29M$519.29M+37.3% vs Q3 2019 Net Income-$21.64M-$21.64MN/M vs Q3 2019 EPS Diluted-$0.06-$0.06N/M vs Q3 2019 Gross Profit$133,585,000+145.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$44,776,000−68.0% Free Cash Flowderived$33,783,000−73.4% Margins · derivedGross margin25.7%+11.3 pt vs Q3 2019
Operating margin0.5%+30.1 pt vs Q3 2019
Net margin-4.2%+65.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end